文献速递前列腺癌

基于穿刺活检标本的基因组分类器预测放疗或手术后转移及前列腺癌特异性死亡的能力

Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
PubMed 文献 · Eur Urol · 2017-05-19

该研究纳入235例接受根治性前列腺切除术(RP,n=105)或放疗±雄激素剥夺治疗(RT,n=130)的患者,用诊断性穿刺标本计算Decipher评分。中位随访6年,34例发生转移、11例死于前列腺癌。多变量分析显示活检Decipher是转移的显著预测因子(HR 1.37/10%评分升高,95%CI 1.06-1.78,p=0.018),也是前列腺癌特异性死亡(PCSM)的显著预测因子(HR 1.57/10%评分升高,95%CI 1.03-2.48,p=0.037)。

要点

  • 活检Decipher可预测以中高危为主、接受一线RP或RT患者的前列腺癌转移。
  • 活检Decipher联合CAPRA或NCCN风险分组可提高对转移的预测区分度。
  • Decipher低、中、高风险组5年PCSM率分别为0%、0%、9.4%。

核心结论

  • 活检Decipher可从诊断性穿刺标本预测以中高危为主、接受一线RT或RP男性的转移和PCSM。

研究设计与样本

  • 研究纳入235例患者,接受RP(n=105)或RT±雄激素剥夺治疗(n=130),来自七家三级转诊中心,均有诊断性穿刺标本的基因组表达谱。
  • 对最高级别癌核心进行采样,基于锁定的随机森林模型计算Decipher。

主要发现

  • 中位随访6年(删失患者中),34例发生转移,11例死于前列腺癌。
  • 多变量分析调整临床变量后,活检Decipher仍是转移的显著预测因子(风险比1.37/10%评分升高,95%CI 1.06-1.78,p=0.018)。
  • 预测活检后5年转移,CAPRA的c-index为0.60(95%CI 0.50-0.69),CAPRA联合活检Decipher的c-index为0.71(95%CI 0.60-0.82)。
  • 预测活检后5年转移,NCCN风险分组的c-index为0.66(95%CI 0.53-0.77),NCCN联合活检Decipher的c-index为0.74(95%CI 0.66-0.82)。
  • 活检Decipher是PCSM的显著预测因子(风险比1.57/10%评分升高,95%CI 1.03-2.48,p=0.037),Decipher低、中、高风险组5年PCSM率分别为0%、0%、9.4%。

临床怎么用

  • 作者结论认为活检Decipher可从诊断性穿刺标本预测以中高危为主、接受一线RT或RP男性的转移和PCSM。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Decipher is a validated genomic classifier developed to determine the biological potential for metastasis after radical prostatectomy (RP). OBJECTIVE: To evaluate the ability of biopsy Decipher to predict metastasis and Prostate cancer-specific mortality (PCSM) in primarily intermediate- to high-risk patients treated with RP or radiation therapy (RT). DESIGN, SETTING, AND PARTICIPANTS: Two hundred and thirty-five patients treated with either RP (n=105) or RT±androgen deprivation therapy (n=130) with available genomic expression profiles generated from diagnostic biopsy specimens from seven tertiary referral centers. The highest-grade core was sampled and Decipher was calculated based on a locked random forest model. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Metastasis and PCSM were the primary and secondary outcomes of the study, respectively. Cox analysis and c-index were used to evaluate the performance of Decipher. RESULTS AND LIMITATIONS: With a median follow-up of 6 yr among censored patients, 34 patients developed metastases and 11 died of prostate cancer. On multivariable analysis, biopsy Decipher remained a significant predictor of metastasis (hazard ratio: 1.37 per 10% increase in score, 95% confidence interval [CI]: 1.06-1.78, p=0.018) after adjusting for clinical variables. For predicting metastasis 5-yr post-biopsy, Cancer of the Prostate Risk Assessment score had a c-index of 0.60 (95% CI: 0.50-0.69), while Cancer of the Prostate Risk Assessment plus biopsy Decipher had a c-index of 0.71 (95% CI: 0.60-0.82). National Comprehensive Cancer Network risk group had a c-index of 0.66 (95% CI: 0.53-0.77), while National Comprehensive Cancer Network plus biopsy Decipher had a c-index of 0.74 (95% CI: 0.66-0.82). Biopsy Decipher was a significant predictor of PCSM (hazard ratio: 1.57 per 10% increase in score, 95% CI: 1.03-2.48, p=0.037), with a 5-yr PCSM rate of 0%, 0%, and 9.4% for Decipher low, intermediate, and high, respectively. CONCLUSIONS: Biopsy Decipher predicted metastasis and PCSM from diagnostic biopsy specimens of primarily intermediate- and high-risk men treated with first-line RT or RP. PATIENT SUMMARY: Biopsy Decipher predicted metastasis and prostate cancer-specific mortality risk from diagnostic biopsy specimens.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Nguyen PL, Haddad Z, Ross AE, et al. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol. 2017. PMID: 28528811. doi:10.1016/j.eururo.2017.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。